<DOC>
	<DOCNO>NCT00817206</DOCNO>
	<brief_summary>This 2-armed parallel group , prospective , randomize , open-label , multicenter Phase 3 control trial establish efficacy safety conversion maintenance immunosuppressive therapy Prograf® capsule ( tacrolimus , Astellas Pharma US , Inc. , Deerfield , IL ) twice daily maintenance immunotherapy LCP Tacro™ tablet ( tacrolimus , LifeCycle Pharma A/S , Hoersholm , Denmark ) daily prevention acute allograft rejection stable adult kidney transplant patient . Patients stable dose Prograf® randomly assign convert Prograf® twice daily LCP Tacro™ daily remain maintenance therapy Prograf® twice daily . Patients enter study treat assigned study drug follow one year patient survival incidence graft rejection graft loss .</brief_summary>
	<brief_title>Safety Efficacy LCP-Tacro™ Once Daily Stable Renal Transplant Patients Converted From Prograf® Twice Daily</brief_title>
	<detailed_description>This 2-armed parallel group , prospective , randomize , open-label , multicenter Phase 3 control trial establish efficacy safety conversion maintenance immunosuppressive therapy Prograf capsule ( tacrolimus , Astellas Pharma US , Inc. , Deerfield , IL ) twice daily maintenance immunotherapy LCP-Tacro tablet ( tacrolimus , LifeCycle Pharma A/S , Horsholm , Denmark ) daily prevention acute allograft rejection stable adult make female kidney transplant patient . Recipients kidney transplant 3 month 5 year Screening stable dose Prograf randomly assign convert Prograf twice daily LCP-Tacro daily remain maintenance therapy Prograf twice daily . There 11 study visit Treatment period .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Men woman least 18 year age recipients kidney transplant 3 month 5 year screen date Patients take oral Prograf® capsule twice daily , least 2 mg total dose per day , part maintenance immunosuppression therapy , tacrolimus trough level 5 15 ng/mL Women childbearing potential must negative serum urine pregnancy test within 7 day receive study drug Recipients transplant organ kidney Recipients bone marrow transplant Patients eGFR ( MDRD7 ) &lt; 30 mL/min Screening Patients spot protein : creatinine ratio &gt; 0.5 Patients WBC count ≤ 2.8 ´ 109/L unless WBC count stable least 2 week absolute neutrophil count &gt; 1.0 ´ 109 /L Patients unable swallow study medication Patients incapable understanding purpose risk study , give write informed consent unwilling unable comply study protocol requirement Pregnant nursing woman Patients reproductive potential unwilling/unable use double barrier method contraception Patients treat investigational agent within 3 month Screening Patients take sirolimus everolimus within 3 month Screening Patients concurrent immunosuppression MMF ( CellCept ) MPS delayedrelease tablet ( Myfortic ) stable dos least 4 week Screening Patients withdrawn corticosteroid le 30 day Screening Patients episode acute rejection require antibody therapy within 3 month Screening Patients treat acute rejection within 30 day Screening Patients hepatitis C virus ( HCV ) negative receive HCV positive ( HCV RNA polymerase chain reaction HCV antibody ) donor kidney Patients seropositive human immunodeficiency virus Patients current malignancy history malignancy ( within past 5 year ) , except basal nonmetastatic squamous cell carcinoma skin treat successfully Patients uncontrolled concomitant infection , systemic infection require treatment , unstable medical condition could interfere study objective Patients severe diarrhea , vomit , active peptic ulcer , gastrointestinal disorder may affect absorption tacrolimus Patients form current substance abuse , psychiatric disorder , condition , opinion investigator , may invalidate communication investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>maintenance immunosuppression</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>Prevention acute allograft rejection</keyword>
</DOC>